Overview
Corporate Philosophy
Research program
Compliance
Business Activities
Natural plant extracts
Health raw materials
Pharmaceutical intermediates
Cosmetic Ingredients
Semi-finished
Medical supplies
Epidemic prevention materials
Sustaining Corporate Value
CSR Activities and Targets
Organizational Governance
PoliciesCorporate Citizenship
Labor
OEM in LiXin
OEM Research Efforts
OEM Product
OEM Organizations
Quality assurance
Quality Control
Production equipment
Testing Equipment
GAP
Qinling green industrial park
Latest News Release
2020-05-07
Obtained VIC quality certification in March 2020
2021-02-25
Ministry of Foreign Affairs documents
2021-09-17
Corporate Video
2021-09-15
Coenzyme Q10 production base was completed and put into production in May 2019
2019-05-13
API CHINA OF Guang Zhou
2015-03-11
Shaanxi LiXin Biotechnology Co., Ltd. to introduce the latest atomized extraction and separation technology
Information
2020-04-09
Our company ceases cooperation with Alibaba International Station in April 2020
2021-01-01
New Years Day holiday notice
2021-09-15
The current situation, prospects and suggestions of China-Africa medical cooperation during the new crown epidemic
2020-07-06
Lycopene No. 2 workshop was completed and put into production
2015-03-11
Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken
2015-03-11
Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken
Reports & Publications
Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken
Relationship with Society
Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken